Compare Google Inc (GOOG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Sanofi SA — how do they compare? Google Inc trades at $350.35 (market cap $4.24T), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Google Inc is far larger — about 44.5× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Sanofi SA for 94 Days on average.
| GOOG | SNY | |
|---|---|---|
Market Cap | $4.24T | $95.18B |
Volume | 13,937,902 | 2,995,646 |
Sector | Media | Health |
52-Week High | $399.06 | $52.34 |
52-Week Low | $237.49 | $39.51 |
Typical Hold Time | 137 Days | 94 Days |
Enterprise Value | $4.13T | $114.48B |
Dividend Yield | 0.26% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $350.02, up 0.76% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 32.8% net margins and consistent earnings beats, though significant capital expenditures have led to negative free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target, representing 24% upside potential from current levels.
The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors face risks from escalating capital spending, regulatory scrutiny, and multiple class-action lawsuits. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, supported by robust cash flow generation and expanding cloud revenue streams.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
